Zeo ScientifiX, Inc. financial data

Symbol
ZEOX on OTC
Location
3321 College Avenue, Suite 246, Davie, FL
State of incorporation
NV
Fiscal year end
October 31
Former names
Organicell Regenerative Medicine, Inc. (to 1/29/2024), Biotech Products Services & Research, Inc. (to 6/15/2018), BESPOKE TRICYCLES INC (to 9/14/2015)
Latest financial report
10-Q - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 38.9 % -18.7%
Quick Ratio 7.19 % -8.06%
Debt-to-equity -212 % +44.5%
Return On Assets -267 % -28.1%
Operating Margin -119 % +4.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.34M shares +3.58%
Common Stock, Shares, Outstanding 6.34M shares +3.58%
Entity Public Float 4.72M USD -34.4%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 6.34M shares +2.49%
Weighted Average Number of Shares Outstanding, Diluted 6.34M shares +2.49%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 4.56M USD -1.85%
Cost of Revenue 876K USD +55.6%
Research and Development Expense 93.7K USD -91.2%
General and Administrative Expense 9.09M USD -7.56%
Operating Income (Loss) -5.41M USD +5.98%
Nonoperating Income (Expense) 32K USD -78.5%
Net Income (Loss) Attributable to Parent -4.91M USD +14.5%
Earnings Per Share, Basic -0.77 USD/shares +7.23%
Earnings Per Share, Diluted -0.77 USD/shares +7.23%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 6K USD -92.2%
Inventory, Net 245K USD -22.5%
Assets, Current 1.09M USD -42.4%
Property, Plant and Equipment, Net 460K USD -13.7%
Assets 1.55M USD -36.3%
Employee-related Liabilities, Current 667K USD 0%
Liabilities, Current 3.35M USD -14.6%
Liabilities 3.36M USD -14.8%
Retained Earnings (Accumulated Deficit) -63.5M USD -8.38%
Stockholders' Equity Attributable to Parent -1.81M USD -19.7%
Liabilities and Equity 1.55M USD -36.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 65K USD
Net Cash Provided by (Used in) Financing Activities -2K USD +77.8%
Common Stock, Shares Authorized 2.5B shares 0%
Common Stock, Shares, Issued 6.34M shares +3.58%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 720K USD -38.6%
Deferred Tax Assets, Valuation Allowance 6.53M USD +17.6%
Deferred Tax Assets, Gross 6.84M USD +16.7%
Depreciation 73K USD -24%
Property, Plant and Equipment, Gross 770K USD 0%
Operating Lease, Liability, Current 49.8K USD -58%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 61.6M USD +8.09%
Depreciation, Depletion and Amortization 18K USD -5.26%
Interest Expense 87K USD -78.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%